Authors: Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC PMID: 32876695 PMCID: PMC7489411 DOI: 10.1001/jama.2020.17021 Abstract Importance: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. Objective: To determine [...]

Authors: Jonathan A C Sterne, Srinivas Murthy, Janet V Diaz, et al. PMID: 32876694 PMCID: PMC7489434 DOI: 10.1001/jama.2020.17023 Abstract Importance: Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support. Objective: To estimate the [...]

Proton pump inhibitors (PPIs) increase the risk for enteric infections that is likely related to PPI-induced hypochlorhydria. Although the impact of acid suppression on severe acute respiratory syndrome coronavirus 2 is unknown thus far, previous data revealed that pH ≤3 impairs the infectivity of the similar severe acute respiratory syndrome coronavirus 1. Thus, we aimed to determine whether use of PPIs increases the odds for acquiring coronavirus disease 2019 (COVID-19) among community-dwelling Americans.

Authors: Lehrer S, Rheinstein PH PMID: 32871846 PMCID: PMC7652439 DOI: 10.21873/invivo.12134 Abstract Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking [...]

Authors: DiNicolantonio JJ, Barroso-Arranda J, McCarty M PMID: 32895293 PMCID: PMC7476419 DOI: 10.1136/openhrt-2020-001350 Abstract Ivermectin, on the WHO’s List of Essential Medications, has been in clinical use since 1981 as an orally and topically active agent for treating a range of parasitic infections in humans, including river blindness and lymphatic filariasis. It is also widely [...]

Authors: Schiaffino MT, Di Natale M, Garcia-Martinez E, Navarro J, Munoz-Blanco JL, Demelo-Rodriguez P PMID: 32738141 PMCID: PMC7454719 DOI: 10.1093/infdis/jiaa485 Abstract Background: During the coronavirus disease 2019 (COVID-19) pandemic, we detected a new immunofluorescence (IF) pattern in serum autoantibody (autoAb) screening of laboratory-confirmed COVID-19 patients. Methods: The IF pattern was composed of liver and gastric [...]

Authors: Senniappan K, Jeyabalan S, Rangappa P, Kanchi M PMID: 33437070 PMCID: PMC7791429 DOI: 10.4103/ija.IJA_613_20 Abstract The coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Although 85% of infected patients remain asymptomatic, 5% show severe symptoms such as hypoxaemic respiratory failure and multiple end organ dysfunction (MODS) [...]

Authors: Sethia R, Prasad M, Mahapatra SJ, Nischal N, Soneja M doi: https://doi.org/10.1101/2020.09.28.20203463 Abstract Background Coronavirus Disease 2019 (COVID-19) pandemic continues unabated in many parts of the world. In the absence of any definite antiviral therapy except some benefit of remdesivir, there is an ongoing search for effective therapy. Famotidine has been shown to reduce [...]

Objective: To determine if hydroxychloroquine (HCQ) reduces the incidence of new illness, hospitalization or death among outpatients at risk for or infected with SARS-CoV-2 (COVID-19).

The COVID-19 disease course is strikingly divergent. Approximately 80-85% of patients experience mild or no symptoms, while the remainder develop severe disease.